HLVX
HilleVax
--
--(--)
Market Open: --
--
--(--)
Post-Market: --
Signals Analysis
Buy signal 1
Sell signal 0
EPS Beats Expectation
Key Stats
--DAY`S RANGE--
--52 WK RANGE--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
About HLVX
Hillevax, Inc.
A biopharmaceutical company that developing novel vaccines for the prevention of moderate-to-severe acute gastroenteritis caused by norovirus infection
321 Harrison Avenue, Boston, Massachusetts 02118
--
HilleVax, Inc., was incorporated in Delaware on March 25, 2020. The company is a clinical-stage biopharmaceutical company focused on developing and commercializing novel vaccines. The company's initial project, HIL -214, is a virus-like particle (VLP) -based vaccine candidate for the prevention of moderate to severe acute gastroenteritis (AGE) caused by norovirus infection. The company plans to initiate a Phase 2b clinical trial in the second quarter of 2022 to evaluate the safety, immunogenicity and efficacy of HIL -214 in infants.
Company Financials
EPS
HLVX has released its 2024 Q4 earnings. EPS was reported at -0.68, versus the expected -0.29, missing expectations. The chart below visualizes how HLVX has performed over recent quarters, highlighting trends in earnings surprises.
Forecast
Wall Street Opinions
Price Target
Volume Profile
Trade Flow Insight
Seasonals
Community Forum
Loading...
Related News
No articles available
